Lilly To Release Data Targeting Key Cancer Pathways At AACR 2014 - - BioPharm International

ADVERTISEMENT

Lilly To Release Data Targeting Key Cancer Pathways At AACR 2014



Eli Lilly will present early-stage data from several targeted cancer therapies–including bemaciclib (LY2835219), its oral, cell-cycle inhibitor of CDK4/6–that make up its clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014. Lilly's oncology pipeline includes a range of large and small molecules being investigated to treat variety of cancers including lung, breast, colorectal, gastric, liver, and hematologic malignancies.

Data from bemaciclib as a potential treatment for metastatic breast cancer, has been accepted as a presentation at AACR's Clinical Trials Symposium and will be featured in an AACR-sponsored press conference.

Lilly's B-Raf inhibitor LY3009120 will be displayed at AACR's New Drugs on the Horizon special session where there will be discussions regarding new anti-cancer compounds that target key pathways. There will also be an oral presentation on Lilly's c-MET kinase inhibitor, LY2801653.

Source: Eli Lilly

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here